This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Texas Biotechnology Corporation, Structural Bioinformatics Inc.. Active years: 1996-2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1996-2003
Title: Kalyanaraman Ramnarayan: Innovator in Endothelin Modulation
Introduction
Kalyanaraman Ramnarayan is a notable inventor based in San Diego, CA, with a focus on innovative solutions in the field of biochemistry. He holds three patents that contribute significantly to the understanding and treatment of endothelin-mediated disorders.
Latest Patents
His latest patents include the development of benzenesulfonamides that modulate the activity of endothelin. These patents detail methods for inhibiting the binding of endothelin peptides to their receptors, as well as increasing the activity of these peptides through the use of specific sulfonamides. Notably, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides have been highlighted for their potential as endothelin receptor B antagonists. Furthermore, his work includes methods for treating inflammatory diseases, such as asthma, by administering effective amounts of these sulfonamides or their prodrugs.
Career Highlights
Kalyanaraman has worked with several prominent companies, including Texas Biotechnology Corporation and Structural Bioinformatics Inc. His contributions in these roles have been instrumental in advancing research and development in his field.
Collaborations
He has collaborated with notable professionals such as Venkatachalapathi Yalamoori and Ming Fai Chan, enhancing the impact of his work through teamwork and shared expertise.
Conclusion
Kalyanaraman Ramnarayan's innovative contributions to the field of endothelin modulation demonstrate his commitment to advancing medical science and improving treatment options for various disorders. His patents and collaborations reflect a significant impact on biochemistry and therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile